This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original articles
Regan, M. M. et al. Treatment-free survival after immune checkpoint inhibitor therapy versus targeted therapy for advanced renal cell carcinoma: 42-month results of the CheckMate 214 trial. Clin. Cancer Res. https://doi.org/10.1158/1078-0432.CCR-21-2283 (2021)
Emamekhoo, H. et al. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920. Cancer https://doi.org/10.1002/cncr.34016 (2021)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stone, L. Entering the endgame for advanced RCC?. Nat Rev Urol 19, 4 (2022). https://doi.org/10.1038/s41585-021-00547-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-021-00547-0